Clinical trial NCT05646459: Effect of Local Cannabidiol on Clinical and Inflammatory Outcomes in Periodontal Maintenance Patients.
Official title: Effect of Local Cannabidiol on Clinical and Inflammatory Outcomes in Periodontal Maintenance Patients.
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE1
Conditions: Periodontitis, Adult
Inflammation Gum
Lead sponsor: University of Nebraska
Sponsor class: OTHER
First posted: 2022-12-12
Enrollment: 0
Sex: ALL
Minimum age (years): 40
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study will determine if cannabidiol (CBD) has any effect on local inflammation in periodontal maintenance patients. Many successful therapies exist for the active, untreated periodontal patient. Unfortunately, periodontology has not yet discovered a therapy that will predictably treat local inflammation in patients who are at risk for further pocketing, bleeding on probing, bone loss and ultimately, tooth loss. Although CBD has been patented in various forms since the 1940s, its acceptance and availability to patients has only recently expanded. Marketing of CBD to periodontal patients as a means to control inflammation is commonplace online and in CBD-specific shops. In determining if CBD is a successful supplement to conventional periodontal inflammation control therapies, millions of patients could benefit from this treatment.

Detailed description: The purpose of this study is to determine if CBD has any effect on local inflammation in periodontal maintenance patients. This research is significant and innovative as it will act as a pivotal study to determine if CBD is worthy of further study in the area of periodontal disease and it will be a human clinical trial focusing on a specific aspect of periodontal disease, the maintenance patient. Many successful therapies exist for the active, untreated periodontal patient. Unfortunately, periodontology has not yet discovered a therapy that will predictably treat local inflammation in these patients which are at risk for further pocketing, bleeding on probing, bone loss and ultimately, tooth loss. Although CBD has been patented in various forms since the 1940s, its acceptance and availability to patients has only recently expanded exponentially. Marketing of CBD to periodontal patients as a means to control inflammation is already commonplace online and in CBD-specific shops; it is the duty of periodontology to determine the efficacy and success of this known anti-inflammatory compound as it relates to clinical periodontal parameters. To determine if CBD is a successful adjunct to conventional periodontal inflammation control therapies would be a boon to the advancement of oral health and to millions of patients that could benefit from this treatment.

Eligibility criteria: Inclusion Criteria:

* diagnosis of chronic moderate-advanced periodontitis
* one 6-9 mm interproximal probing depth
* overall good systemic health
* history of regular PMT

Exclusion Criteria:

* systemic disease that significantly affect periodontal inflammation and bone turnover
* surgical periodontal therapy in the past year
* pregnant/breast-feeding females.

Primary outcomes:
measure: Clinical Attachment Level
timeFrame: baseline
measure: Clinical Attachment Level
timeFrame: 6 months
Secondary outcomes:
measure: Inflammatory Biomarkers
timeFrame: baseline
measure: Inflammatory Biomarkers
timeFrame: 6 months
Other outcomes:
Locations:
Study officials:
affiliation: UNMC College of Dentistry
name: Joseph B Bavitz, DMD
role: STUDY_CHAIR
References: